Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious

BACKGROUND: A median progression free survival (PFS) of 18–20 months and median overall survival (OS) of 51–57 months can be achieved with the use of imatinib, in metastatic or advanced gastrointestinal stromal tumor (GIST). Sunitinib and regorafenib are approved options for patients progressing on...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Gastrointest Oncol
Asıl Yazarlar: Ramaswamy, Anant, Pande, Nikhil, Shetty, Omshree, Shetty, Nitin, Gupta, Sudeep, Ostwal, Vikas
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AME Publishing Company 2016
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4963378/
https://ncbi.nlm.nih.gov/pubmed/27563456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.03.06
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller